Pluristem Therapeutics Announces Interim Results from PLX-PAD Clinical Trials
Data Suggests PLX-PAD is Safe and Potentially Efficacious
HAIFA, Israel, Jan 11, 2010 (BUSINESS WIRE) -- Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced interim results from their Phase I clinical trials utilizing their placenta derived cell therapy product, PLX-PAD, for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD). Data suggested that PLX-PAD is safe and potentially efficacious.
Nine patients, representing one-third of the patients needed to complete the Phase I dose-escalating studies in the U.S. and Germany, have been dosed with PLX-PAD. Patients experienced no significant unfavorable effects related to PLX-PAD administration. Three of the nine patients dosed completed their three-month follow up and the data from those patients demonstrated a trend towards efficacy with a reduction in their Rutherford Category, a measure of the severity of their limb ischemia.
"The interim results are in line with the data from the first patient treated with PLX-PAD," said Professor Doctor Andre Schmidt-Lucke, Director of the Franziskus-Krankenhaus Institute of Berlin, Germany. "We are encouraged by the consistency of the data and believe that PLX-PAD may be an effective treatment for CLI."
Zami Aberman, chairman and CEO of Pluristem, added, "The interim results are a significant milestone for Pluristem as we advance in our Phase I clinical trials to further test the safety and potential efficacy of PLX-PAD."
About Pluristem
Pluristem is a clinical stage biotechnology company with proprietary technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem's patented and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases. |
